97
Participants
Start Date
May 13, 2019
Primary Completion Date
September 9, 2020
Study Completion Date
September 9, 2020
Elsubrutinib
Elsubrutinib capsule will be administered orally.
Upadacitinib
Upadacitinib tablet will be administered orally.
Placebo for elsubrutinib
Placebo capsule for elsubrutinib will be administered orally.
Placebo for upadacitinib
Upadacitinib placebo tablet will be administered orally.
Revita Reumatologiai Rendelo /ID# 208187, Budapest
Cliniques Universitaires Saint Luc /ID# 207719, Woluwe-Saint-Lambert
UZ Leuven /ID# 207722, Leuven
CRU Hungary Egeszsegugyi és Szolgaltato Kft. /ID# 208186, Miskolc
Szabolcs-Szatmar-Bereg Megyei Korhazak & Egyetemi Oktatokorhaz /ID# 208184, Nyíregyháza
CMED Rehabilitacios es Diagnosztikai Kozpont /ID# 208188, Székesfehérvár
Vital Medical Center Orvosi-es Fogaszati Kozpont /ID# 208185, Veszprém
Hospital Universitario A Coruña - CHUAC /ID# 207732, A Coruña
Hospital Universitario Virgen de las Nieves /ID# 209975, Granada
Hospital Clinico Universitario San Carlos /ID# 207738, Madrid
Hospital Regional de Malaga /ID# 207735, Málaga
Hospital Unversitario Marques de Valdecilla /ID# 207729, Santander
Hospital Universitario y Politecnico La Fe /ID# 207739, Valencia
Hospital Universitario Basurto /ID# 207737, Bilbao
Rheumatology Research Assoc /ID# 207769, Edmonton
Manitoba Clinic /ID# 206852, Winnipeg
CIADS Research Co Ltd /ID# 206853, Winnipeg
Mount Sinai Hosp.-Toronto /ID# 206851, Toronto
Dr. Latha Naik /ID# 213440, Saskatoon
Revmatolog s.r.o. /ID# 209941, Jihlava
Revmatologicky ustav Praha /ID# 209943, Prague
Revmatologie MUDr. Klara Sirova /ID# 209944, Ostrava
CCR Czech a.s /ID# 209942, Pardubice
Malopolskie Centrum Kliniczne /ID# 209902, Krakow
McBk Sc /Id# 212577, Grodzisk Mazowiecki
NBR Polska /ID# 209904, Warsaw
ClinicMed Daniluk, Nowak Sp.j. /ID# 212578, Bialystok
Reumatika - Centrum Reumatologii NZOZ /ID# 209903, Warsaw
Hospital Clinic /ID# 207740, Barcelona
University of Oxford /ID# 210571, Oxford
Lead Sponsor
AbbVie
INDUSTRY